Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Venetoclax and azacitidine for AML ineligible for standard induction

Raúl Córdoba • 22 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Venetoclax
VIALE-A

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores the use of venetoclax and azacitidine in older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy, as evaluated in the VIALE-A study (NCT02993523) presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
1:30
The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba • 15 Jun 2024
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
1:11
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raúl Córdoba • 15 Jun 2024
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
1:27
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raúl Córdoba • 15 Jun 2024
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Raúl Córdoba • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Raúl Córdoba • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Raúl Córdoba • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Raúl Córdoba • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals